Literature DB >> 8139009

A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats.

W F Goins1, L R Sternberg, K D Croen, P R Krause, R L Hendricks, D J Fink, S E Straus, M Levine, J C Glorioso.   

Abstract

Herpes simplex virus type 1 (HSV-1) expresses a unique series of RNA molecules, the latency-associated transcripts or LATs, during latent infection of neuronal tissues. Previous studies by others have described a TATA box-containing latency-active promoter, referred to here as LAP1, located approximately 700 bp upstream of the 5' end of the major 2.0-kb LAT. In this report, transient gene expression assays were employed to identify a second, novel latency-active promoter (LAP2) present within a region downstream of LAP1 and 5' proximal to the major 2.0-kb LAT. In contrast to LAP1, this promoter lacks a TATA box but possesses cis-acting regulatory elements and other features frequently observed within eukaryotic housekeeping gene promoters. Unlike most other HSV promoters, LAP2 was down-regulated by the viral transcriptional activators ICP4 and ICP0. The majority of LAP2-positive regulatory elements were located within sequences from -257 to -58 relative to the 5' end of the 2.0-kb LAT, and the basal promoter mapped within sequences from -14 to +28. RNase protection experiments demonstrated that chimeric LAT-chloramphenicol acetyltransferase transcripts produced in the transient assays initiated at or near the 5' end of the major 2-kb LAT. Tn5 insertional mutagenesis of the ICP4 regulatory gene determined that down-regulation of LAP2 required the ICP4 transactivating domain and targeted the minimal promoter region as the site of action by ICP4. Replicating recombinant viruses containing a LAP2-lacZ reporter gene cassette in an ectopic site (glycoprotein C locus) were shown to be active in mouse trigeminal ganglia. Taken together, these experiments suggest that the LAT region of the HSV-1 genome contains at least two latency-active promoters which may play different roles in expressing the various LATs. Alternatively, these promoters may comprise a larger promoter-regulatory complex which may influence transcription during latency.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139009      PMCID: PMC236700     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

1.  Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse.

Authors:  D Y Ho; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  A nuclease-hypersensitive element of the human c-myc promoter interacts with a transcription initiation factor.

Authors:  E H Postel; S E Mango; S J Flint
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

4.  A cis-acting transcription element of the c-myc gene can assume an H-DNA conformation.

Authors:  A J Kinniburgh
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175.

Authors:  R A Dixon; P A Schaffer
Journal:  J Virol       Date:  1980-10       Impact factor: 5.103

7.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

8.  Abnormal properties of an immediate early polypeptide in cells infected with the herpes simplex virus type 1 mutant tsK.

Authors:  C M Preston
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

9.  ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB.

Authors:  C A Smith; P Bates; R Rivera-Gonzalez; B Gu; N A DeLuca
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Cloning of herpes simplex virus type 1 sequences representing the whole genome.

Authors:  A L Goldin; R M Sandri-Goldin; M Levine; J C Glorioso
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

View more
  66 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region.

Authors:  H Berthomme; J Thomas; P Texier; A Epstein; L T Feldman
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.

Authors:  J A Palmer; R H Branston; C E Lilley; M J Robinson; F Groutsi; J Smith; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo.

Authors:  Maryam Ahmed; Martin Lock; Cathie G Miller; Nigel W Fraser
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 6.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 7.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

8.  Herpes Simplex Virus 2 Latency-Associated Transcript (LAT) Region Mutations Do Not Identify a Role for LAT-Associated MicroRNAs in Viral Reactivation in Guinea Pig Genital Models.

Authors:  Yoshiki Kawamura; Marta Bosch-Marce; Shuang Tang; Amita Patel; Philip R Krause
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

9.  Two open reading frames (ORF1 and ORF2) within the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1 are not essential for reactivation from latency.

Authors:  M U Fareed; J G Spivack
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.